Description of the medicine: Octreotide (Octreotide)

OCTREOTIDE.

A synonym for Sandostatin, Sandostatin, Somatostatinum.

Synthetic peptide (octapeptide), close in structure and action to natural (endogenous) somatostatin, but differs significantly more stability and duration of action.

Octreotide with a subcutaneous injection is rapidly absorbed; The maximum concentration in the blood plasma is reached within 30 minutes; When administered intravenously, is released into 2 phases with a half-life of 10 and 90 minutes.

Apply octreotide (sandostatin) to reduce the concentration of growth hormone in acromegaly, including in cases of insufficient effectiveness of dopamine agonists (seeBromokpiptin); For the removal of symptoms associated with endocrine tumors of the gatro-entero-pancreatic system; For the prevention of complications after operations on the pancreas; With profuse secretory diarrhea and reflex diarrhea associated with AIDS, dumping syndrome, astrum pancreatitis.

Assign usually subcutaneously. In acromegaly, 0.05-0.1 mg (50-100 μg) is administered at intervals of 8 or 12 hours. The dose is refined based on the determination of the growth hormone concentration, clinical symptoms, tolerability. Typically, the optimal daily dose is 0.3 mg. The maximum oral dose is 1.5 mg.

For endocrine tumors of the gatro-entero-pancreatic system, 0.05 mg (50 μg) is administered 1-2 times per day, with a gradual increase (if necessary) up to 3 times a day.

With diarrhea, 0.1-0.2 mg is administered 2-3 times a day for 5-7 days.

With refractory diarrhea associated with AIDS, enter 0.1-0.2 mg 3 times a day (if necessary, up to 0.3 and more mg 3 times a day).

To prevent complications after surgery on the pancreas, administer 0.1 mg 3 times daily for 7 days, starting 1 hour before surgery.

The daily dose should not usually exceed 0.75 mg (750 mcg) for adults.

Children should be administered at a rate of 0.001-0.01 mg (1-10 μg) per 1 kg of body weight.

Subcutaneous injections of the drug are painful.

In some cases, resort to intravenous injection.

Octreotide must be used under close medical supervision with laboratory tests.

Local side effects include pain, itching, burning at the injection site.

Anorexia, nausea, vomiting, abdominal pain, diarrhea, steatorrhea may be present.

There are violations of glucose tolerance and liver function, the appearance of stones in the biliary tract (with prolonged use of the drug).

Sometimes pituitary tumors that produce somatotropin can increase.

During pregnancy and lactation, the use of sandostatin is possible only on absolute indications.

Form release: solution for injection in ampoules containing 0.05; 0.1 or 0.5 mg (50; 100 or 500 μg) in 1 ml; Reusable vials containing 1 mg (1000 μg) in 5 ml of solvent.

Storage: at a temperature of +2 to +8 C (up to 2 weeks at room temperature).